Goldman Sachs Initiates Coverage On Iovance Biotherapeutics with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan has initiated coverage on Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy rating and set a price target of $12.
November 20, 2023 | 9:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Iovance Biotherapeutics with a Buy rating and a price target of $12.
The initiation of coverage by Goldman Sachs with a Buy rating typically indicates a positive outlook on the stock, suggesting that the analyst sees potential upside. The announcement of a price target higher than the current market price can lead to increased investor interest and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100